New Products Posted to GenomeWeb: Precipio, Seq2Know, Stratify Genomics

Oct 05, 2018

|

Precipio HemeScreen

Precipio has commercially launched HemeScreen, a test for mutations in hematologic cancers. The test measures for mutations in the CALR, JAK2, and MPL genes, as well as in exon 12 of JAK2, all of which are critically important to developing a clinical roadmap for the patient, Precipio said. The company will offer the assay through its CLIA laboratory in New Haven, Connecticut, and will also offer a set of RUO reagents to other reference labs to perform the test in their CLIA laboratories.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Keep Them or Not?

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

Dunno Whose It Is

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

Knowing Risk From a Young Age

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

Science Translational Medicine Paper Finds Drug Combo Boosts KRAS Inhibitor Efficacy in Lung Cancer

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.

Menu